Company Filing History:
Years Active: 2017-2023
Title: Ying Shen: A Pioneer in Eukaryotic Expression Systems
Introduction
Ying Shen, based in Yorktown Heights, NY, is an accomplished inventor recognized for his significant contributions in the field of biotechnology. With a total of three patents to his name, Shen's work focuses on the enhancement of recombinant protein expression in eukaryotic cells, paving the way for advancements in therapeutic developments.
Latest Patents
Shen's latest patents revolve around "CHO integration sites and uses thereof," which provide expression-enhancing nucleotide sequences for eukaryotic expression systems. These innovations allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Specifically, his patents offer genomic integration sites that facilitate improved expression and methods for utilizing these sites to express a gene of interest in eukaryotic cells. The patents also describe chromosomal loci, sequences, and vectors that contribute to enhanced and stable expression of genes in eukaryotic systems.
Career Highlights
Currently, Ying Shen is employed at Regeneron Pharmaceuticals, Inc., a company renowned for its dedication to transforming scientific innovation into life-saving medicines. His role within the organization allows him to leverage his expertise in biotechnology and genetic engineering, further contributing to the realm of recombinant protein expression.
Collaborations
Throughout his career, Shen has collaborated with fellow researchers such as Darya Burakov and Gang Chen. These partnerships have fostered an environment of innovation and have propelled his work in developing advanced methodologies for gene expression in eukaryotic cells.
Conclusion
Ying Shen's pioneering inventions in the field of biotechnology highlight his commitment to advancing scientific knowledge and improving health outcomes through enhanced eukaryotic expression systems. As he continues to innovate within his field, his contributions represent the cutting edge of genomic research and therapeutic development.